Accropeutics Secures $12M in Series B+ Funding

Accropeutics Inc., a pioneering biotechnology company with a focus on innovative therapeutics for immune-mediated diseases, has successfully concluded its Series B Plus financing round, securing approximately $12 million. Shenzhen Capital Group (SCGC) led the investment, with further contributions from ongoing supporter Morningside Ventures and new participants Leader Venture Investment (SZTI) and Hefei Sci-Tec Venture Capital (HFST). This financial boost extends the company's cash runway until the latter half of 2026, setting the stage for continued advancements in its clinical programs.

The funds from this round will be strategically utilized to further clinical research on the company's key asset, AC-101, a RIPK2 inhibitor currently in a Phase Ib trial for Ulcerative Colitis (UC) patients. Accropeutics is also advancing other clinical-stage products, including AC-201, a selective TYK2/JAK1 inhibitor undergoing a Phase II trial for moderate-to-severe Psoriasis, and AC-003, a RIPK1 inhibitor in a Phase Ib study for acute Graft-versus-Host Disease (aGvHD). In addition to these, the company has an array of immune and inflammatory (I&I) assets in preclinical development stages.

Dr. Xiaohu (Jason) Zhang, Co-founder and CEO of Accropeutics, expressed gratitude toward both existing and new investors for their confidence in the company's vision. He emphasized that this financial support will enable Accropeutics to continue progressing its leading programs and strengthening its position as a pioneering clinical-stage biotech firm. The company aims to revolutionize treatment options for a broad range of I&I diseases with potential best-in-class therapies.

Accropeutics, with its headquarters in New York and Suzhou, is dedicated to the discovery, development, and commercialization of novel treatments for immune-mediated inflammatory conditions. By targeting the molecular mechanisms of regulated cell death, Accropeutics boasts a robust pipeline of compounds in various stages of development, from initial optimization to advanced clinical trials.

AC-101, the company's RIPK2 inhibitor, has completed Phase I trials in both Australia and China and is being tested in a Phase Ib trial for UC. Similarly, AC-201, targeting TYK2/JAK1, has progressed from Phase I trials in Australia and China to a Phase II trial in China for Psoriasis. Additionally, AC-003, focused on RIPK1 inhibition, has completed Phase I trials in China and the US and is currently in a Phase Ib trial for aGvHD. Beyond these clinical candidates, Accropeutics' research pipeline includes several preclinical assets.

The company holds worldwide rights to its therapeutic assets and maintains a strong intellectual property portfolio, with 23 patents issued across China, Japan, Korea, the United States, and the European Union. This extensive patent collection underscores Accropeutics' commitment to innovative therapeutic approaches and positions the company as a leader in its field.

By focusing on the molecular dynamics of regulated cell death, Accropeutics aims to open new possibilities for treating immune-mediated diseases, potentially transforming the therapeutic landscape for patients worldwide. With the additional financing, the company is well-positioned to advance its innovative pipeline and capitalize on emerging opportunities in the biotech industry.